1368488
2016
1
heidelberg-university-faculty-of-medicine
50
creator
asc
year
1
225
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XMPDSNWQ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bernard%20et%20al.%22%2C%22parsedDate%22%3A%222016-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBernard%2C%20J.%2C%20Armand-Lef%26%23xE8%3Bvre%2C%20L.%2C%20Luce%2C%20E.%2C%20Mniai%2C%20A.%20E.%2C%20Chau%2C%20F.%2C%20Casalino%2C%20E.%2C%20Andremont%2C%20A.%20and%20Rupp%26%23xE9%3B%2C%20E.%20%282016%29.%20%3Cb%3EImpact%20of%20a%20short%20exposure%20to%20levofloxacin%20on%20faecal%20densities%20and%20relative%20abundance%20of%20total%20and%20quinolone-resistant%20Enterobacteriaceae%3C%5C%2Fb%3E.%20Clinical%20Microbiology%20and%20Infection%20%3Ci%3E22%3C%5C%2Fi%3E%2C%20646.e1-646.e4%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2016.04.015%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2016.04.015%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20a%20short%20exposure%20to%20levofloxacin%20on%20faecal%20densities%20and%20relative%20abundance%20of%20total%20and%20quinolone-resistant%20Enterobacteriaceae%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Armand-Lef%5Cu00e8vre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Luce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20El%22%2C%22lastName%22%3A%22Mniai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Casalino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Andremont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Rupp%5Cu00e9%22%7D%5D%2C%22abstractNote%22%3A%22Emergence%20of%20resistant%20Enterobacteriaceae%20in%20the%20intestinal%20microbiota%20during%20antibiotic%5Cntreatment%20is%20well%20documented%20but%20its%20early%20dynamic%20is%20not.%20Here%2C%20we%20compared%20the%20densities%5Cnof%20total%20Enterobacteriaceae%20and%20relative%20abundance%20%28RA%29%20of%20quinolone-resistant%20Enterobacteriaceae%5Cn%28QRE%29%20in%20the%20first%20stool%20passed%20by%20patients%20who%20had%20a%20short%20exposure%20to%20levofloxacin%5Cn%28levofloxacin%2C%20n%3D12%29%20or%20not%20%28control%2C%20n%3D8%29.%20Mean%20densities%20%28SD%29%20%28log%20CFU%5C%2Fg%20stool%29%5Cnof%20total%20Enterobacteriaceae%20were%20lower%20in%20the%20levofloxacin%20group%20than%20in%20the%20control%5Cngroup%5Cu20143.4%20%281.6%29%20versus%206.7%20%281.7%29%2C%20respectively%2C%20p%20%3C0.001.%22%2C%22date%22%3A%222016%5C%2F07%5C%2F01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2016.04.015%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.clinicalmicrobiologyandinfection.com%5C%2Farticle%5C%2FS1198-743X%2816%2930091-X%5C%2Fabstract%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-03-02T22%3A40%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22W4SXQV97%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bernard%20et%20al.%22%2C%22parsedDate%22%3A%222016-09-07%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBernard%2C%20C.%2C%20Aubry%2C%20A.%2C%20Chauffour%2C%20A.%2C%20Brossier%2C%20F.%2C%20Robert%2C%20J.%20and%20Veziris%2C%20N.%20%282016%29.%20%3Cb%3EIn%20vivo%20Mycobacterium%20tuberculosis%20fluoroquinolone%20resistance%20emergence%3A%20a%20complex%20phenomenon%20poorly%20detected%20by%20current%20diagnostic%20tests%3C%5C%2Fb%3E.%20J%20Antimicrob%20Chemother%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw344%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw344%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22In%20vivo%20Mycobacterium%20tuberculosis%20fluoroquinolone%20resistance%20emergence%3A%20a%20complex%20phenomenon%20poorly%20detected%20by%20current%20diagnostic%20tests%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Heteroresistance%2C%20described%20both%20in%20terms%20of%20various%20point%20mutations%20resulting%20in%20different%20levels%20of%20resistance%20and%20in%20terms%20of%20a%20mixture%20of%20mutant%20and%20WT%20bacilli%2C%20is%20identified%20in%20up%20to%20one-third%20of%20fluoroquinolone%20%28FQ%29-resistant%20Mycobacterium%20tuberculosis%20isolates.%20Heteroresistance%20is%20a%20challenge%20for%20current%20phenotypic%20and%20genotypic%20susceptibility%20testing%20%28DST%29%20regimes.%20We%20aimed%20to%20compare%20the%20performances%20of%20different%20phenotypic%20and%20genotypic%20DST%20in%20the%20context%20of%20FQ%20heteroresistance%20by%20mimicking%2C%20in%20a%20murine%20model%2C%20the%20course%20of%20selection%20of%20FQ%20resistance%20during%20treatment.%5CnMETHODS%3A%20The%20capacity%20of%20different%20phenotypic%20DST%20%5BLowenstein-Jensen%20%28LJ%29%20medium%20containing%20either%202%20mg%5C%2FL%20ofloxacin%20or%200.5%2C%201%20or%202%20mg%5C%2FL%20moxifloxacin%5D%20and%20genotypic%20DST%20%28gyrA%5C%2FB%20Sanger%20sequencing%29%20to%20detect%20FQ%20resistance%20was%20analysed.%5CnRESULTS%3A%20Ninety-seven%20percent%20of%20mice%20harboured%20a%20heterogeneous%20population.%20The%20proportion%20of%20mice%20in%20which%20FQ%20resistance%20was%20detected%20varied%20according%20to%20the%20medium%20used%20%2897%25%20for%200.5%20mg%5C%2FL%20moxifloxacin%2C%2080%25%20for%202%20mg%5C%2FL%20ofloxacin%2C%2047%25%20for%201%20mg%5C%2FL%20moxifloxacin%20and%2025%25%20for%202%20mg%5C%2FL%20moxifloxacin%29.%20Compared%20with%20phenotypic%20DST%2C%20genotypic%20DST%20had%20a%20low%20sensitivity%20for%20detection%20of%20resistance%20%2833%25%29.%5CnCONCLUSIONS%3A%20Our%20study%20shows%20the%20in%20vivo%20complexity%20of%20FQ%20resistance%20emergence%20and%20the%20poor%20sensitivity%20of%20Sanger%20DNA%20sequencing%20for%20detection%20of%20heteroresistance.%20Our%20data%20support%20the%20use%20of%200.5%20mg%5C%2FL%20moxifloxacin%20in%20LJ%20for%20detection%20of%20FQ%20resistance%2C%20but%20not%20the%20recent%20increase%20in%20the%20ofloxacin%20critical%20concentration%20from%202%20to%204%20mg%5C%2FL%20given%20in%20the%20WHO%20recommendations.%22%2C%22date%22%3A%22Sep%207%2C%202016%22%2C%22language%22%3A%22ENG%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkw344%22%2C%22ISSN%22%3A%221460-2091%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-01-08T18%3A02%3A04Z%22%7D%7D%2C%7B%22key%22%3A%2282KFKIR3%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20and%20Aubry%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrossier%2C%20F.%20and%20Aubry%2C%20A.%20%282016%29.%20%3Cb%3ERe%26%23x301%3Bsistance%20de%20Mycobacterium%20tuberculosis%20aux%20antituberculeux%3C%5C%2Fb%3E.%20Feuillets%20Bio%20%3Ci%3E328%3C%5C%2Fi%3E%2C%2017%26%23x2013%3B25%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1684%5C%2Fabc.2016.1132%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1684%5C%2Fabc.2016.1132%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Re%5Cu0301sistance%20de%20Mycobacterium%20tuberculosis%20aux%20antituberculeux%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1684%5C%2Fabc.2016.1132%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T16%3A23%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22IKHZHS3H%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20et%20al.%22%2C%22parsedDate%22%3A%222016-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrossier%2C%20F.%2C%20Guindo%2C%20D.%2C%20Pham%2C%20A.%2C%20Reibel%2C%20F.%2C%20Sougakoff%2C%20W.%2C%20Veziris%2C%20N.%20and%20Aubry%2C%20A.%20%282016%29.%20%3Cb%3EPerformance%20of%20the%20New%20Version%20%28v2.0%29%20of%20the%20GenoType%20MTBDRsl%20Test%20for%20Detection%20of%20Resistance%20to%20Second-Line%20Drugs%20in%20Multidrug-Resistant%20Mycobacterium%20tuberculosis%20Complex%20Strains%3C%5C%2Fb%3E.%20J%20Clin%20Microbiol%20%3Ci%3E54%3C%5C%2Fi%3E%2C%201573%26%23x2013%3B1580%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.00051-16%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1128%5C%2FJCM.00051-16%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Performance%20of%20the%20New%20Version%20%28v2.0%29%20of%20the%20GenoType%20MTBDRsl%20Test%20for%20Detection%20of%20Resistance%20to%20Second-Line%20Drugs%20in%20Multidrug-Resistant%20Mycobacterium%20tuberculosis%20Complex%20Strains%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Guindo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Pham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Reibel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Detecting%20resistance%20to%20fluoroquinolones%20%28FQ%29%20and%20second-line%20injectable%20drugs%20%28amikacin%20%5BAMK%5D%2C%20kanamycin%20%5BKAN%5D%2C%20and%20capreomycin%20%5BCAP%5D%29%20is%20crucial%20given%20the%20worldwide%20increase%20in%20the%20incidence%20of%20extensively%20drug-resistant%20tuberculosis%20%28XDR-TB%29.%20A%20new%20version%20of%20the%20GenoType%20MTBDRsl%20test%20%28v2.0%29%20has%20been%20developed%20to%20improve%20the%20detection%20of%20resistance%20to%20FQ%20%28involving%20gyrA%20and%20gyrB%20mutations%29%20and%20to%20second-line%20injectable%20drugs%20%28involving%20rrs%20and%20eis%20promoter%20mutations%29%20in%20Mycobacterium%20tuberculosis%20A%20collection%20of%20127%20multidrug-resistant%20%28MDR%29%20M.%20tuberculosis%20complex%20strains%20was%20tested%20using%20the%20first%20%28v1%29%20and%20second%20%28v2.0%29%20versions%20of%20the%20MTBDRsl%20test%2C%20as%20well%20as%20DNA%20sequencing.%20The%20specificities%20in%20resistance%20detection%20of%20v1%20and%20v2.0%20were%20similar%20throughout%2C%20whereas%20the%20levels%20of%20sensitivity%20of%20v2.0%20were%20superior%20for%20FQ%20%2894.8%25%20versus%2089.6%25%29%20and%20KAN%20%2890.5%25%20versus%2059.5%25%29%20but%20similar%20for%20AMK%20%2891.3%25%29%20and%20CAP%20%2883.0%25%29.%20The%20sensitivity%20and%20specificity%20of%20v2.0%20were%20superior%20to%20those%20of%20v1%20for%20the%20detection%20of%20pre-XDR%20strains%20%2883.3%25%20versus%2075.0%25%20and%2088.6%25%20versus%2067.1%25%2C%20respectively%29%2C%20whereas%20the%20sensitivity%20of%20v2.0%20was%20superior%20to%20that%20of%20v1%20only%20for%20the%20detection%20of%20XDR%20strains%20%2883.0%25%20versus%2049.1%25%29.%20In%20conclusion%2C%20MTBDRsl%20v2.0%20is%20superior%20to%20MTBDRsl%20v1%20and%20efficiently%20detects%20the%20most%20common%20mutations%20involved%20in%20resistance%20to%20FQ%20and%20aminoglycosides%5C%2FCAP.%20However%2C%20due%20to%20mutations%20not%20recognized%20by%20v2.0%20or%20to%20the%20presence%20of%20resistance%20mechanisms%20not%20yet%20characterized%20%28particularly%20mechanisms%20related%20to%20monoresistance%20to%20aminoglycosides%20or%20CAP%29%2C%20the%20results%20for%20wild-type%20strains%20obtained%20with%20MTBDRsl%20v2.0%20should%20be%20confirmed%20by%20further%20DNA%20sequencing%20and%20phenotypic%20drug%20susceptibility%20testing.%22%2C%22date%22%3A%22Jun%202016%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1128%5C%2FJCM.00051-16%22%2C%22ISSN%22%3A%221098-660X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-07-17T13%3A51%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22QH92KQPE%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20et%20al.%22%2C%22parsedDate%22%3A%222016-12-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrossier%2C%20F.%2C%20Cambau%2C%20E.%2C%20Tessier%2C%20E.%2C%20Jarlier%2C%20V.%20and%20Sougakoff%2C%20W.%20%282016%29.%20%3Cb%3EThe%20in%26%23xA0%3Bvitro%20mechanisms%20of%20isoniazid%20and%20ethionamide%20resistance%20poorly%20reflect%20those%20in%26%23xA0%3Bvivo%20in%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20Tuberculosis%20%3Ci%3E101%3C%5C%2Fi%3E%2C%20144%26%23x2013%3B145%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tube.2016.09.028%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tube.2016.09.028%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20in%5Cu00a0vitro%20mechanisms%20of%20isoniazid%20and%20ethionamide%20resistance%20poorly%20reflect%20those%20in%5Cu00a0vivo%20in%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Tessier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22December%201%2C%202016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.tube.2016.09.028%22%2C%22ISSN%22%3A%221472-9792%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1472979216303766%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T16%3A12%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22MXPTFNZS%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brossier%20et%20al.%22%2C%22parsedDate%22%3A%222016-09-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBrossier%2C%20F.%2C%20Boudinet%2C%20M.%2C%20Jarlier%2C%20V.%2C%20Petrella%2C%20S.%20and%20Sougakoff%2C%20W.%20%282016%29.%20%3Cb%3EComparative%20study%20of%20enzymatic%20activities%20of%20new%20KatG%20mutants%20from%20low-%20and%20high-level%20isoniazid-resistant%20clinical%20isolates%20of%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20Tuberculosis%20%3Ci%3E100%3C%5C%2Fi%3E%2C%2015%26%23x2013%3B24%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tube.2016.06.002%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.tube.2016.06.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparative%20study%20of%20enzymatic%20activities%20of%20new%20KatG%20mutants%20from%20low-%20and%20high-level%20isoniazid-resistant%20clinical%20isolates%20of%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marl%5Cu00e8ne%22%2C%22lastName%22%3A%22Boudinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Petrella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%5D%2C%22abstractNote%22%3A%22Resistance%20to%20isoniazid%20%28INH-R%29%20in%20Mycobacterium%20tuberculosis%20is%20mainly%20due%20to%20mutations%20at%20position%20315%20%28S315T%29%20of%20the%20catalase-peroxidase%20KatG.%20We%20identified%2016%20mutations%20%28including%2013%20biochemically%20uncharacterized%20mutations%29%20in%20KatG%20from%20INH-R%20clinical%20isolates%20of%20M.%5Cu00a0tuberculosis%20showing%20mutations%20other%20than%20S315T.%20The%20KatG%20enzymatic%20activities%20%28catalase%2C%20peroxidase%2C%20free%20radical%20production%20and%20isonicotinoyl-NAD%20formation%29%20of%20wild-type%20KatG%20and%20the%2016%20mutants%20were%20determined%20and%20correlated%20to%20their%20spatial%20location%20in%20a%20KatG%20model%20structure.%20Of%20all%20mutations%20studied%2C%20H270R%2C%20which%20conferred%20a%20high%20level%20of%20INH-R%20and%20results%20in%20the%20disruption%20of%20a%20coordination%20bond%20with%20the%20heme%2C%20caused%20complete%20loss%20of%20all%20enzymatic%20KatG%20activities.%20The%20mutants%20generally%20associated%20with%20a%20very%20high%20level%20of%20INH-R%20were%20all%20characterized%20by%20a%20drastic%20reduction%20in%20catalase%20activity%20and%20a%20marked%20decrease%20in%20INH%20activation%20activities.%20One%20mutant%2C%20A162E%2C%20displayed%20a%20behavior%20similar%20to%20S315T%2C%20i.e.%20a%20moderate%20decrease%20in%20catalase%20activity%20and%20a%20drastic%20decrease%20in%20the%20formation%20of%20the%20radical%20form%20of%20INH.%20Finally%2C%20the%20mutants%20associated%20with%20a%20low%20level%20of%20INH-R%20showed%20a%20moderate%20reduction%20in%20the%20four%20catalytic%20activities%2C%20likely%20stemming%20from%20an%20overall%20alteration%20of%20the%20folding%20and%5C%2For%20stability%20of%20the%20KatG%20protein.%22%2C%22date%22%3A%22September%201%2C%202016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.tube.2016.06.002%22%2C%22ISSN%22%3A%221472-9792%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1472979216300403%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T16%3A09%3A47Z%22%7D%7D%2C%7B%22key%22%3A%223Z54DDAJ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chauffour%20et%20al.%22%2C%22parsedDate%22%3A%222016-10-18%22%2C%22numChildren%22%3A6%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChauffour%2C%20A.%2C%20Robert%2C%20J.%2C%20Veziris%2C%20N.%2C%20Aubry%2C%20A.%20and%20Jarlier%2C%20V.%20%282016%29.%20%3Cb%3ESterilizing%20Activity%20of%20Fully%20Oral%20Intermittent%20Regimens%20against%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%3C%5C%2Fb%3E.%20PLOS%20Neglected%20Tropical%20Diseases%20%3Ci%3E10%3C%5C%2Fi%3E%2C%20e0005066%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0005066%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0005066%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sterilizing%20Activity%20of%20Fully%20Oral%20Intermittent%20Regimens%20against%20Mycobacterium%20ulcerans%20Infection%20in%20Mice%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%5D%2C%22abstractNote%22%3A%22Author%20Summary%20Buruli%20ulcer%2C%20caused%20by%20Mycobacterium%20ulcerans%2C%20is%20the%20third%20most%20frequent%20disease%20due%20to%20a%20bacteria%20of%20the%20mycobacteria%20family%2C%20after%20tuberculosis%20and%20leprosy.%20The%20disease%20consists%20of%20a%20cutaneous%20infection%20leading%20to%20skin%20ulcerations%20that%20can%20cause%20severe%20and%20debilitating%20scars.%20It%20occurs%20mostly%20in%20Africa%20where%20access%20to%20healthcare%20is%20still%20difficult.%20Until%20recently%2C%20surgery%20was%20the%20only%20way%20to%20treat%20Buruli%20ulcer.%20Recently%2C%20a%20medical%20treatment%20based%20on%20two%20antibiotics%20%28rifampin%20and%20streptomycin%29%20was%20found%20to%20be%20active%20in%20an%20experimental%20infection%20model%20and%20was%20recommended%20by%20WHO%20in%202004%20for%20humans.%20A%20drawback%20of%20this%20new%20medical%20approach%20is%20a%20long%20and%20daily%20administration%20%282%20months%29%20of%20streptomycin%2C%20an%20aminoglycoside%2C%20which%20requires%20daily%20injections%20and%20can%20have%20secondary%20effects.%20In%20our%20research%2C%20we%20sought%20to%20find%20a%20fully%20oral%20and%20intermittent%20treatment%20to%20facilitate%20the%20management%20of%20the%20patients%20on%20the%20field.%20The%20antibiotics%20combinations%20we%20studied%20were%20efficient%20in%20our%20model%20and%20would%20need%20now%20to%20be%20tested%20on%20the%20field.%22%2C%22date%22%3A%2218%20oct.%202016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0005066%22%2C%22ISSN%22%3A%221935-2735%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosntds%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pntd.0005066%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-11T23%3A51%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22W88HJZMM%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chazel%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChazel%2C%20M.%2C%20Marchandin%2C%20H.%2C%20Keck%2C%20N.%2C%20Terru%2C%20D.%2C%20Carri%26%23xE8%3Bre%2C%20C.%2C%20Ponsoda%2C%20M.%2C%20Jacomo%2C%20V.%2C%20Panteix%2C%20G.%2C%20Bouzinbi%2C%20N.%2C%20Ba%26%23xF1%3Buls%2C%20A.-L.%2C%20Choisy%2C%20M.%2C%20Solassol%2C%20J.%2C%20Aubry%2C%20A.%20and%20Godreuil%2C%20S.%20%282016%29.%20%3Cb%3EEvaluation%20of%20the%20SLOMYCO%20Sensititre%26%23xAE%3B%20panel%20for%20testing%20the%20antimicrobial%20susceptibility%20of%20Mycobacterium%20marinum%20isolates%3C%5C%2Fb%3E.%20Annals%20of%20Clinical%20Microbiology%20and%20Antimicrobials%20%3Ci%3E15%3C%5C%2Fi%3E%2C%2030%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12941-016-0145-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12941-016-0145-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evaluation%20of%20the%20SLOMYCO%20Sensititre%5Cu00ae%20panel%20for%20testing%20the%20antimicrobial%20susceptibility%20of%20Mycobacterium%20marinum%20isolates%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Chazel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Marchandin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Keck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Terru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Carri%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Ponsoda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Jacomo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Panteix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Bouzinbi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Ba%5Cu00f1uls%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Choisy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Solassol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Godreuil%22%7D%5D%2C%22abstractNote%22%3A%22The%20agar%20dilution%20method%20is%20currently%20considered%20as%20the%20reference%20method%20for%20Mycobacterium%20marinum%20drug%20susceptibility%20testing%20%28DST%29.%20As%20it%20is%20time-consuming%2C%20alternative%20methods%2C%20such%20as%20the%20E-test%2C%20were%20evaluated%20for%20M.%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20marinum%20DST%2C%20but%20without%20success.%20The%20SLOMYCO%20Sensititre%5Cu00ae%20panel%2C%20recently%20commercialized%20by%20TREK%20Diagnostic%20Systems%20%28Cleveland%2C%20OH%29%2C%20can%20be%20used%20for%20DST%20in%20slow-growing%20mycobacteria%20and%20for%20antimicrobial%20agents%20recommended%20by%20the%20Clinical%20and%20Laboratory%20Standards%20Institute%20%28CLSI%29%20for%20M.%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20marinum%20DST.%20The%20main%20goal%20of%20this%20work%20was%20to%20evaluate%20the%20SLOMYCO%20Sensititre%5Cu00ae%20panel%20method%20for%20DST%20in%20M.%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20marinum%20isolates%20from%20human%20patients%20and%20fish%20relative%20to%20the%20reference%20agar%20dilution%20method.%22%2C%22date%22%3A%222016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12941-016-0145-1%22%2C%22ISSN%22%3A%221476-0711%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fdx.doi.org%5C%2F10.1186%5C%2Fs12941-016-0145-1%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-09-18T14%3A29%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22JTUN4R8I%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Crabol%20et%20al.%22%2C%22parsedDate%22%3A%222016-03-23%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECrabol%2C%20Y.%2C%20Catherinot%2C%20E.%2C%20Veziris%2C%20N.%2C%20Jullien%2C%20V.%20and%20Lortholary%2C%20O.%20%282016%29.%20%3Cb%3ERifabutin%3A%20where%20do%20we%20stand%20in%202016%3F%3C%5C%2Fb%3E%20J%20Antimicrob%20Chemother%20dkw024%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw024%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw024%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rifabutin%3A%20where%20do%20we%20stand%20in%202016%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoann%22%2C%22lastName%22%3A%22Crabol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Catherinot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jullien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Lortholary%22%7D%5D%2C%22abstractNote%22%3A%22Rifabutin%20is%20a%20spiro-piperidyl-rifamycin%20structurally%20closely%20related%20to%20rifampicin%20that%20shares%20many%20of%20its%20properties.%20We%20attempted%20to%20address%20the%20reasons%20why%20this%20drug%2C%20which%20was%20recently%20recognized%20as%20a%20WHO%20Essential%20Medicine%2C%20still%20had%20a%20far%20narrower%20range%20of%20indications%20than%20rifampicin%2C%2024%20years%20after%20its%20launch.%20In%20this%20comprehensive%20review%20of%20the%20classic%20and%20more%20recent%20rifabutin%20experimental%20and%20clinical%20studies%2C%20the%20current%20state%20of%20knowledge%20about%20rifabutin%20is%20depicted%2C%20relying%20on%20specific%20pharmacokinetics%2C%20pharmacodynamics%2C%20antimicrobial%20properties%2C%20resistance%20data%20and%20side%20effects%20compared%20with%20rifampicin.%20There%20are%20consistent%20in%20vitro%20data%20and%20clinical%20studies%20showing%20that%20rifabutin%20has%20at%20least%20equivalent%20activity%5C%2Fefficacy%20and%20acceptable%20tolerance%20compared%20with%20rifampicin%20in%20TB%20and%20non-tuberculous%20mycobacterial%20diseases.%20Clinical%20studies%20have%20emphasized%20the%20clinical%20benefits%20of%20low%20rifabutin%20liver%20induction%20in%20patients%20with%20AIDS%20under%20PIs%2C%20in%20solid%20organ%20transplant%20patients%20under%20immunosuppressive%20drugs%20or%20in%20patients%20presenting%20intolerable%20side%20effects%20related%20to%20rifampicin.%20The%20contribution%20of%20rifabutin%20for%20rifampicin-resistant%2C%20but%20rifabutin-susceptible%2C%20Mycobacterium%20tuberculosis%20isolates%20according%20to%20the%20present%20breakpoints%20has%20been%20challenged%20and%20is%20now%20controversial.%20Compared%20with%20rifampicin%2C%20rifabutin%27s%20lower%20AUC%20is%20balanced%20by%20higher%20intracellular%20penetration%20and%20lower%20MIC%20for%20most%20pathogens.%20Clinical%20studies%20are%20lacking%20in%20non-mycobacterial%20infections.%22%2C%22date%22%3A%222016-03-23%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkw024%22%2C%22ISSN%22%3A%220305-7453%2C%201460-2091%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjac.oxfordjournals.org%5C%2Fcontent%5C%2Fearly%5C%2F2016%5C%2F03%5C%2F22%5C%2Fjac.dkw024%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-01-08T18%3A02%3A19Z%22%7D%7D%2C%7B%22key%22%3A%229EJDIMF5%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fox%20et%20al.%22%2C%22parsedDate%22%3A%222016-03-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFox%2C%20G.%20J.%2C%20Benedetti%2C%20A.%2C%20Mitnick%2C%20C.%20D.%2C%20Pai%2C%20M.%2C%20Menzies%2C%20D.%20and%20Mdr-Tb%2C%20T.%20C.%20G.%20for%20M.-A.%20of%20I.%20P.%20D.%20in%20%282016%29.%20%3Cb%3EPropensity%20Score-Based%20Approaches%20to%20Confounding%20by%20Indication%20in%20Individual%20Patient%20Data%20Meta-Analysis%3A%20Non-Standardized%20Treatment%20for%20Multidrug%20Resistant%20Tuberculosis%3C%5C%2Fb%3E.%20PLOS%20ONE%20%3Ci%3E11%3C%5C%2Fi%3E%2C%20e0151724%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0151724%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0151724%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Propensity%20Score-Based%20Approaches%20to%20Confounding%20by%20Indication%20in%20Individual%20Patient%20Data%20Meta-Analysis%3A%20Non-Standardized%20Treatment%20for%20Multidrug%20Resistant%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20J.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Benedetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madhukar%22%2C%22lastName%22%3A%22Pai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22The%20Collaborative%20Group%20for%20Meta-Analysis%20of%20Individual%20Patient%20Data%20in%22%2C%22lastName%22%3A%22Mdr-Tb%22%7D%5D%2C%22abstractNote%22%3A%22Background%20In%20the%20absence%20of%20randomized%20clinical%20trials%2C%20meta-analysis%20of%20individual%20patient%20data%20%28IPD%29%20from%20observational%20studies%20may%20provide%20the%20most%20accurate%20effect%20estimates%20for%20an%20intervention.%20However%2C%20confounding%20by%20indication%20remains%20an%20important%20concern%20that%20can%20be%20addressed%20by%20incorporating%20individual%20patient%20covariates%20in%20different%20ways.%20We%20compared%20different%20analytic%20approaches%20to%20account%20for%20confounding%20in%20IPD%20from%20patients%20treated%20for%20multi-drug%20resistant%20tuberculosis%20%28MDR-TB%29.%20%20%20Methods%20Two%20antibiotic%20classes%20were%20evaluated%2C%20fluoroquinolones%5Cu2014considered%20the%20cornerstone%20of%20effective%20MDR-TB%20treatment%5Cu2014and%20macrolides%2C%20which%20are%20known%20to%20be%20safe%2C%20yet%20are%20ineffective%20in%20vitro.%20The%20primary%20outcome%20was%20treatment%20success%20against%20treatment%20failure%2C%20relapse%20or%20death.%20Effect%20estimates%20were%20obtained%20using%20multivariable%20and%20propensity-score%20based%20approaches.%20%20%20Results%20Fluoroquinolone%20antibiotics%20were%20used%20in%2028%20included%20studies%2C%20within%20which%206%2C612%20patients%20received%20a%20fluoroquinolone%20and%20723%20patients%20did%20not.%20Macrolides%20were%20used%20in%2015%20included%20studies%2C%20within%20which%20459%20patients%20received%20this%20class%20of%20antibiotics%20and%203%2C670%20did%20not.%20Both%20standard%20multivariable%20regression%20and%20propensity%20score-based%20methods%20resulted%20in%20similar%20effect%20estimates%20for%20early%20and%20late%20generation%20fluoroquinolones%2C%20while%20macrolide%20antibiotics%20use%20was%20associated%20with%20reduced%20treatment%20success.%20%20%20Conclusions%20In%20this%20individual%20patient%20data%20meta-analysis%2C%20standard%20multivariable%20and%20propensity-score%20based%20methods%20of%20adjusting%20for%20individual%20patient%20covariates%20for%20observational%20studies%20yielded%20produced%20similar%20effect%20estimates.%20Even%20when%20adjustment%20is%20made%20for%20potential%20confounding%2C%20interpretation%20of%20adjusted%20estimates%20must%20still%20consider%20the%20potential%20for%20residual%20bias.%22%2C%22date%22%3A%2229%20mars%202016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0151724%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosone%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pone.0151724%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-01-08T18%3A09%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22JCCDZBI4%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fox%20et%20al.%22%2C%22parsedDate%22%3A%222016-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFox%2C%20G.%20J.%2C%20Mitnick%2C%20C.%20D.%2C%20Benedetti%2C%20A.%2C%20Chan%2C%20E.%20D.%2C%20Becerra%2C%20M.%2C%20Chiang%2C%20C.-Y.%2C%20Keshavjee%2C%20S.%2C%20Koh%2C%20W.-J.%2C%20Shiraishi%2C%20Y.%2C%20Viiklepp%2C%20P.%2C%20Yim%2C%20J.-J.%2C%20Pasvol%2C%20G.%2C%20Robert%2C%20J.%2C%20Shim%2C%20T.%20S.%2C%20Shin%2C%20S.%20S.%2C%20Menzies%2C%20Dick%2C%20Mdr-Tb%2C%20%20for%20the%20C.%20G.%20for%20M.-A.%20of%20I.%20P.%20D.%20in%2C%20Ahuja%2C%20S.%2C%20Ashkin%2C%20D.%2C%20Avenda%26%23xF1%3Bo%2C%20M.%2C%20Banerjee%2C%20R.%2C%20Bauer%2C%20M.%2C%20Burgos%2C%20M.%2C%20Centis%2C%20R.%2C%20Cobelens%2C%20F.%2C%20Cox%2C%20H.%2C%20D%26%23x2019%3BAmbrosio%2C%20L.%2C%20Lange%2C%20W.%20C.%20M.%20de%2C%20DeRiemer%2C%20K.%2C%20Enarson%2C%20D.%2C%20Falzon%2C%20D.%2C%20Flanagan%2C%20K.%2C%20Flood%2C%20J.%2C%20Gandhi%2C%20N.%2C%20Garcia-Garcia%2C%20L.%2C%20Granich%2C%20R.%20M.%2C%20Hollm-Delgado%2C%20M.%20G.%2C%20Holtz%2C%20T.%20H.%2C%20Hopewell%2C%20P.%2C%20Iseman%2C%20M.%2C%20Jarlsberg%2C%20L.%20G.%2C%20Kim%2C%20H.%20R.%2C%20Lancaster%2C%20J.%2C%20Lange%2C%20C.%2C%20Leimane%2C%20V.%2C%20Leung%2C%20C.%20C.%2C%20Li%2C%20J.%2C%20Menzies%2C%20D.%2C%20Migliori%2C%20G.%20B.%2C%20Narita%2C%20M.%2C%20Nathanson%2C%20E.%2C%20Odendaal%2C%20R.%2C%20O%26%23x2019%3BRiordan%2C%20P.%2C%20Pai%2C%20M.%2C%20Palmero%2C%20D.%2C%20Park%2C%20S.%20K.%2C%20Pena%2C%20J.%2C%20P%26%23xE9%3Brez-Guzm%26%23xE1%3Bn%2C%20C.%2C%20Ponce-de-Leon%2C%20A.%2C%20Quelapio%2C%20M.%20I.%20D.%2C%20Quy%2C%20H.%20T.%2C%20Riekstina%2C%20V.%2C%20Royce%2C%20S.%2C%20Salim%2C%20M.%2C%20Schaaf%2C%20H.%20S.%2C%20Seung%2C%20K.%20J.%2C%20Shah%2C%20L.%2C%20Shean%2C%20K.%2C%20Sifuentes-Osornio%2C%20J.%2C%20Sotgiu%2C%20G.%2C%20Strand%2C%20M.%20J.%2C%20Sung%2C%20S.%20W.%2C%20Tabarsi%2C%20P.%2C%20Tupasi%2C%20T.%20E.%2C%20Vargas%2C%20M.%20H.%2C%20Altena%2C%20R.%20van%2C%20Walt%2C%20M.%20van%20der%2C%20Werf%2C%20T.%20S.%20van%20der%2C%20Westenhouse%2C%20J.%20and%20Yew%2C%20W.%20W.%20%282016%29.%20%3Cb%3ESurgery%20as%20an%20Adjunctive%20Treatment%20for%20Multidrug-Resistant%20Tuberculosis%3A%20An%20Individual%20Patient%20Data%20Metaanalysis%3C%5C%2Fb%3E.%20Clin%20Infect%20Dis%20%3Ci%3E62%3C%5C%2Fi%3E%2C%20887%26%23x2013%3B895%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciw002%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciw002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Surgery%20as%20an%20Adjunctive%20Treatment%20for%20Multidrug-Resistant%20Tuberculosis%3A%20An%20Individual%20Patient%20Data%20Metaanalysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%20J.%22%2C%22lastName%22%3A%22Fox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Benedetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20D.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mercedes%22%2C%22lastName%22%3A%22Becerra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chen-Yuan%22%2C%22lastName%22%3A%22Chiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salmaan%22%2C%22lastName%22%3A%22Keshavjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Won-Jung%22%2C%22lastName%22%3A%22Koh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuji%22%2C%22lastName%22%3A%22Shiraishi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Piret%22%2C%22lastName%22%3A%22Viiklepp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jae-Joon%22%2C%22lastName%22%3A%22Yim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Pasvol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tae%20Sun%22%2C%22lastName%22%3A%22Shim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sonya%20S.%22%2C%22lastName%22%3A%22Shin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22for%20the%20Collaborative%20Group%20for%20Meta-Analysis%20of%20Individual%20Patient%20Data%20in%22%2C%22lastName%22%3A%22Mdr-Tb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ahuja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Ashkin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Avenda%5Cu00f1o%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Banerjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Bauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Burgos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Centis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Cobelens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Cox%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22D%27Ambrosio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20C.%20M.%20de%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22DeRiemer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Enarson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Falzon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Flanagan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Flood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Gandhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Garcia-Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20M.%22%2C%22lastName%22%3A%22Granich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20G.%22%2C%22lastName%22%3A%22Hollm-Delgado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20H.%22%2C%22lastName%22%3A%22Holtz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Hopewell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Iseman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20G.%22%2C%22lastName%22%3A%22Jarlsberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20R.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Lancaster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Leimane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20C.%22%2C%22lastName%22%3A%22Leung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Migliori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Narita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Nathanson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Odendaal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22O%27Riordan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Pai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Palmero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20K.%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Guzm%5Cu00e1n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Ponce-de-Leon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20I.%20D.%22%2C%22lastName%22%3A%22Quelapio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20T.%22%2C%22lastName%22%3A%22Quy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Riekstina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Royce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Salim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20S.%22%2C%22lastName%22%3A%22Schaaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%20J.%22%2C%22lastName%22%3A%22Seung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Shean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Sifuentes-Osornio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sotgiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20J.%22%2C%22lastName%22%3A%22Strand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20W.%22%2C%22lastName%22%3A%22Sung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Tabarsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20E.%22%2C%22lastName%22%3A%22Tupasi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20H.%22%2C%22lastName%22%3A%22Vargas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20van%22%2C%22lastName%22%3A%22Altena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20van%20der%22%2C%22lastName%22%3A%22Walt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%20S.%20van%20der%22%2C%22lastName%22%3A%22Werf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Westenhouse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20W.%22%2C%22lastName%22%3A%22Yew%22%7D%5D%2C%22abstractNote%22%3A%22Background.%20Medical%20treatment%20for%20multidrug-resistant%20%28MDR%29-tuberculosis%20is%20complex%2C%20toxic%2C%20and%20associated%20with%20poor%20outcomes.%20Surgical%20lung%20resection%20may%20be%20used%20as%20an%20adjunct%20to%20medical%20therapy%2C%20with%20the%20intent%20of%20reducing%20bacterial%20burden%20and%20improving%20cure%20rates.%20We%20conducted%20an%20individual%20patient%20data%20metaanalysis%20to%20evaluate%20the%20effectiveness%20of%20surgery%20as%20adjunctive%20therapy%20for%20MDR-tuberculosis.%5CnMethods.%20Individual%20patient%20data%2C%20was%20obtained%20from%20the%20authors%20of%2026%20cohort%20studies%2C%20identified%20from%203%20systematic%20reviews%20of%20MDR-tuberculosis%20treatment.%20Data%20included%20the%20clinical%20characteristics%20and%20medical%20and%20surgical%20therapy%20of%20each%20patient.%20Primary%20analyses%20compared%20treatment%20success%20%28cure%20and%20completion%29%20to%20a%20combined%20outcome%20of%20failure%2C%20relapse%2C%20or%20death.%20The%20effects%20of%20all%20forms%20of%20resection%20surgery%2C%20pneumonectomy%2C%20and%20partial%20lung%20resection%20were%20evaluated.%5CnResults.%20A%20total%20of%204238%20patients%20from%2018%20surgical%20studies%20and%202193%20patients%20from%208%20nonsurgical%20studies%20were%20included.%20Pulmonary%20resection%20surgery%20was%20performed%20on%20478%20patients.%20Partial%20lung%20resection%20surgery%20was%20associated%20with%20improved%20treatment%20success%20%28adjusted%20odds%20ratio%20%5BaOR%5D%2C%203.0%3B%2095%25%20confidence%20interval%20%5BCI%5D%2C%201.5%5Cu20135.9%3B%20I2R%2C%2011.8%25%29%2C%20but%20pneumonectomy%20was%20not%20%28aOR%2C%201.1%3B%2095%25%20CI%2C%20.6%5Cu20132.3%3B%20I2R%2C%2013.2%25%29.%20Treatment%20success%20was%20more%20likely%20when%20surgery%20was%20performed%20after%20culture%20conversion%20than%20before%20conversion%20%28aOR%2C%202.6%3B%2095%25%20CI%2C%200.9%5Cu20137.1%3B%20I2R%2C%200.2%25%29.%5CnConclusions.%20Partial%20lung%20resection%2C%20but%20not%20pneumonectomy%2C%20was%20associated%20with%20improved%20treatment%20success%20among%20patients%20with%20MDR-tuberculosis.%20Although%20improved%20outcomes%20may%20reflect%20patient%20selection%2C%20partial%20lung%20resection%20surgery%20after%20culture%20conversion%20may%20improve%20treatment%20outcomes%20in%20patients%20who%20receive%20optimal%20medical%20therapy.%22%2C%22date%22%3A%2204%5C%2F01%5C%2F2016%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciw002%22%2C%22ISSN%22%3A%221058-4838%2C%201537-6591%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcid.oxfordjournals.org%5C%2Fcontent%5C%2F62%5C%2F7%5C%2F887%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-27T17%3A31%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22KXN8PMNV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222016-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Veziris%2C%20N.%2C%20Caumes%2C%20E.%2C%20Marigot-Outtandy%2C%20D.%2C%20Yazdanpanah%2C%20Y.%2C%20Robert%2C%20J.%20and%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%20%282016%29.%20%3Cb%3EIs%20bedaquiline%20as%20effective%20as%20fluoroquinolones%20in%20the%20treatment%20of%20multidrug-resistant%20tuberculosis%3F%3C%5C%2Fb%3E%20European%20Respiratory%20Journal%20%3Ci%3E48%3C%5C%2Fi%3E%2C%20582%26%23x2013%3B585%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00411-2016%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00411-2016%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Is%20bedaquiline%20as%20effective%20as%20fluoroquinolones%20in%20the%20treatment%20of%20multidrug-resistant%20tuberculosis%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%5D%2C%22abstractNote%22%3A%22Extract%5CnBedaquiline%20%28Bdq%29%20is%20approved%20for%20the%20treatment%20of%20multidrug-resistant%20%28MDR%29%20tuberculosis%20%28TB%29.%20In%20a%20phase%20IIb%20trial%2C%20Bdq%20allowed%20a%20significant%20reduction%20in%20time%20to%20culture%20conversion%20and%20improved%20outcome%20in%20MDR-TB%20patients%20%5B1%2C%202%5D.%20Preliminary%20reports%20of%20Bdq%20compassionate%20use%20have%20shown%20promising%20results%20%5B3%5Cu20135%5D.%20However%2C%20in%20an%20early%20bactericidal%20activity%20%28EBA%29%20study%2C%20the%20association%20of%20moxifloxacin%20%28Mfx%29%20with%20PA-824%20and%20pyrazinamide%20showed%20better%20activity%20than%20Bdq-based%20associations%20%5B6%5D.%20In%20addition%2C%20resistance%20to%20fluoroquinolones%20%28Fq%29%20has%20been%20associated%20with%20poorer%20outcome%20in%20MDR-TB%20before%20Bdq%20use%20%5B7%5D.%20These%20data%20reinforce%20the%20pivotal%20role%20of%20Fq.%20Comparing%20Bdq%20to%20Fq%20in%20interventional%20studies%20is%20challenging.%20Indeed%2C%20the%20paucity%20of%20drugs%20available%20for%20MDR-TB%20treatment%2C%20and%20the%20need%20for%20combination%20therapy%2C%20often%20impose%20the%20need%20to%20use%20all%20available%20drugs.%5CnBedaquiline%20and%20fluoroquinolone%20treatments%20give%20similar%20culture%20conversion%20rates%20at%206%20months%20in%20MDR-TB%20patients%20http%3A%5C%2F%5C%2Fow.ly%5C%2FoqVY300mJCy%22%2C%22date%22%3A%222016%5C%2F08%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00411-2016%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F48%5C%2F2%5C%2F582%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-09-18T14%3A31%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22B97IEKH8%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Henry%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHenry%2C%20B.%2C%20Revest%2C%20M.%2C%20Dournon%2C%20N.%2C%20Epelboin%2C%20L.%2C%20Mellon%2C%20G.%2C%20Bellaud%2C%20G.%2C%20Mordant%2C%20P.%2C%20Le%20D%26%23xFB%3B%2C%20D.%2C%20V%26%23xE9%3Bziris%2C%20N.%2C%20Bernard%2C%20C.%2C%20Morel%2C%20S.%2C%20Jaur%26%23xE9%3Bguiberry%2C%20S.%2C%20Michelet%2C%20C.%2C%20Bricaire%2C%20F.%2C%20Tattevin%2C%20P.%20and%20Caumes%2C%20%26%23xC9%3B.%20%282016%29.%20%3Cb%3EPreliminary%20Favorable%20Outcome%20for%20Medically%20and%20Surgically%20Managed%20Extensively%20Drug-Resistant%20Tuberculosis%2C%20France%2C%202009%26%23x2013%3B2014%3C%5C%2Fb%3E.%20Emerging%20Infectious%20Diseases%20%3Ci%3E22%3C%5C%2Fi%3E%2C%20518%26%23x2013%3B521%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2203.151130%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2203.151130%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preliminary%20Favorable%20Outcome%20for%20Medically%20and%20Surgically%20Managed%20Extensively%20Drug-Resistant%20Tuberculosis%2C%20France%2C%202009%5Cu20132014%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beno%5Cu00eet%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Revest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Dournon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Epelboin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mellon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Bellaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Mordant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Le%20D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22V%5Cu00e9ziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Jaur%5Cu00e9guiberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Michelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Bricaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Tattevin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9ric%22%2C%22lastName%22%3A%22Caumes%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2203%5C%2F2016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2203.151130%22%2C%22ISSN%22%3A%221080-6040%2C%201080-6059%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwwwnc.cdc.gov%5C%2Feid%5C%2Farticle%5C%2F22%5C%2F3%5C%2F15-1130_article.htm%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-09-18T14%3A30%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22GZ4KD98U%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lach%5Cu00e2tre%20et%20al.%22%2C%22parsedDate%22%3A%222016-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELach%26%23xE2%3Btre%2C%20M.%2C%20Rioux%2C%20C.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Veziris%2C%20N.%2C%20Bouvet%2C%20E.%20and%20Yazdanpanah%2C%20Y.%20%282016%29.%20%3Cb%3EBedaquiline%20plus%20delamanid%20for%20XDR%20tuberculosis%3C%5C%2Fb%3E.%20Lancet%20Infect%20Dis%20%3Ci%3E16%3C%5C%2Fi%3E%2C%20294%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2816%2900047-5%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2816%2900047-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Bedaquiline%20plus%20delamanid%20for%20XDR%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Lach%5Cu00e2tre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Bouvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Mar%202016%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2816%2900047-5%22%2C%22ISSN%22%3A%221474-4457%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-04-06T12%3A56%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22BBGVJEMN%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lafeuille%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELafeuille%2C%20E.%2C%20Veziris%2C%20N.%2C%20Sougakoff%2C%20W.%2C%20Roure%2C%20F.%2C%20Le%20D%26%23xFB%3B%2C%20D.%2C%20Dournon%2C%20N.%2C%20Caumes%2C%20E.%2C%20Jarlier%2C%20V.%2C%20Aubry%2C%20A.%2C%20Robert%2C%20J.%20and%20Bernard%2C%20C.%20%282016%29.%20%3Cb%3EXDR-tuberculosis%20in%20France%3A%20Community%20transmission%20due%20to%20non-compliance%20with%20isolation%20precautions%3C%5C%2Fb%3E.%20M%26%23xE9%3Bdecine%20et%20Maladies%20Infectieuses%20%3Ci%3E46%3C%5C%2Fi%3E%2C%2052%26%23x2013%3B55%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2015.12.008%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2015.12.008%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22XDR-tuberculosis%20in%20France%3A%20Community%20transmission%20due%20to%20non-compliance%20with%20isolation%20precautions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Lafeuille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Roure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Le%20D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Dournon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2202%5C%2F2016%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.medmal.2015.12.008%22%2C%22ISSN%22%3A%220399077X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Flinkinghub.elsevier.com%5C%2Fretrieve%5C%2Fpii%5C%2FS0399077X15003091%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-03-26T17%3A53%3A43Z%22%7D%7D%2C%7B%22key%22%3A%226E5QJBC3%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lange%20et%20al.%22%2C%22parsedDate%22%3A%222016-09-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELange%2C%20C.%2C%20Duarte%2C%20R.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Guenther%2C%20G.%2C%20Guglielmetti%2C%20L.%2C%20Olaru%2C%20I.%20D.%2C%20Oliveira%2C%20O.%2C%20Rumetshofer%2C%20R.%2C%20Veziris%2C%20N.%20and%20van%20Leth%2C%20F.%20%282016%29.%20%3Cb%3ELimited%20Benefit%20of%20the%20New%20Shorter%20Multidrug-Resistant%20Tuberculosis%20Regimen%20in%20Europe%3C%5C%2Fb%3E.%20Am%20J%20Respir%20Crit%20Care%20Med%20%3Ci%3E194%3C%5C%2Fi%3E%2C%201029%26%23x2013%3B1031%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1164%5C%2Frccm.201606-1097LE%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1164%5C%2Frccm.201606-1097LE%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Limited%20Benefit%20of%20the%20New%20Shorter%20Multidrug-Resistant%20Tuberculosis%20Regimen%20in%20Europe%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22Guenther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioana%20D.%22%2C%22lastName%22%3A%22Olaru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olena%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rudolf%22%2C%22lastName%22%3A%22Rumetshofer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22van%20Leth%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22septembre%2029%2C%202016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1164%5C%2Frccm.201606-1097LE%22%2C%22ISSN%22%3A%221073-449X%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.atsjournals.org%5C%2Fdoi%5C%2Fabs%5C%2F10.1164%5C%2Frccm.201606-1097LE%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-01-08T18%3A05%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22THGEPMJ5%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lortholary%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELortholary%2C%20O.%2C%20Roussillon%2C%20C.%2C%20Boucherie%2C%20C.%2C%20Padoin%2C%20C.%2C%20Chaix%2C%20M.-L.%2C%20Breton%2C%20G.%2C%20Rami%2C%20A.%2C%20Veziris%2C%20N.%2C%20Patey%2C%20O.%2C%20Caumes%2C%20E.%2C%20May%2C%20T.%2C%20Molina%2C%20J.-M.%2C%20Robert%2C%20J.%2C%20Tod%2C%20M.%2C%20Fagard%2C%20C.%20and%20Ch%26%23xEA%3Bne%2C%20G.%20%282016%29.%20%3Cb%3ETenofovir%20DF%5C%2Femtricitabine%20and%20efavirenz%20combination%20therapy%20for%20HIV%20infection%20in%20patients%20treated%20for%20tuberculosis%3A%20the%20ANRS%20129%20BKVIR%20trial%3C%5C%2Fb%3E.%20Journal%20of%20Antimicrobial%20Chemotherapy%20%3Ci%3E71%3C%5C%2Fi%3E%2C%20783%26%23x2013%3B793%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkv384%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkv384%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tenofovir%20DF%5C%2Femtricitabine%20and%20efavirenz%20combination%20therapy%20for%20HIV%20infection%20in%20patients%20treated%20for%20tuberculosis%3A%20the%20ANRS%20129%20BKVIR%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Lortholary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Roussillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Boucherie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Padoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Chaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Breton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agathe%22%2C%22lastName%22%3A%22Rami%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Patey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22May%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Tod%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Fagard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevi%5Cu00e8ve%22%2C%22lastName%22%3A%22Ch%5Cu00eane%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2203%5C%2F2016%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkv384%22%2C%22ISSN%22%3A%220305-7453%2C%201460-2091%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.jac.oxfordjournals.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1093%5C%2Fjac%5C%2Fdkv384%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-02-26T17%3A51%3A07Z%22%7D%7D%2C%7B%22key%22%3A%2296NQCXTI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mieras%20et%20al.%22%2C%22parsedDate%22%3A%222016-06-08%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMieras%2C%20L.%2C%20Anthony%2C%20R.%2C%20van%20Brakel%2C%20W.%2C%20Bratschi%2C%20M.%20W.%2C%20van%20den%20Broek%2C%20J.%2C%20Cambau%2C%20E.%2C%20Cavaliero%2C%20A.%2C%20Kasang%2C%20C.%2C%20Perera%2C%20G.%2C%20Reichman%2C%20L.%2C%20Richardus%2C%20J.%20H.%2C%20Saunderson%2C%20P.%2C%20Steinmann%2C%20P.%20and%20Yew%2C%20W.%20W.%20%282016%29.%20%3Cb%3ENegligible%20risk%20of%20inducing%20resistance%20in%20Mycobacterium%20tuberculosis%20with%20single-dose%20rifampicin%20as%20post-exposure%20prophylaxis%20for%20leprosy%3C%5C%2Fb%3E.%20Infectious%20Diseases%20of%20Poverty%20%3Ci%3E5%3C%5C%2Fi%3E%2C%2046%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40249-016-0140-y%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40249-016-0140-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Negligible%20risk%20of%20inducing%20resistance%20in%20Mycobacterium%20tuberculosis%20with%20single-dose%20rifampicin%20as%20post-exposure%20prophylaxis%20for%20leprosy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liesbeth%22%2C%22lastName%22%3A%22Mieras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Anthony%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wim%22%2C%22lastName%22%3A%22van%20Brakel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20W.%22%2C%22lastName%22%3A%22Bratschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22van%20den%20Broek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arielle%22%2C%22lastName%22%3A%22Cavaliero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christa%22%2C%22lastName%22%3A%22Kasang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geethal%22%2C%22lastName%22%3A%22Perera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%22%2C%22lastName%22%3A%22Reichman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20Hendrik%22%2C%22lastName%22%3A%22Richardus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Saunderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Steinmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wing%20Wai%22%2C%22lastName%22%3A%22Yew%22%7D%5D%2C%22abstractNote%22%3A%22Post-exposure%20prophylaxis%20%28PEP%29%20for%20leprosy%20is%20administered%20as%20one%20single%20dose%20of%20rifampicin%20%28SDR%29%20to%20the%20contacts%20of%20newly%20diagnosed%20leprosy%20patients.%20SDR%20reduces%20the%20risk%20of%20developing%20leprosy%20among%20contacts%20by%20around%2060%5Cu00a0%25%20in%20the%20first%202%5Cu20133%20years%20after%20receiving%20SDR.%20In%20countries%20where%20SDR%20is%20currently%20being%20implemented%20under%20routine%20programme%20conditions%20in%20defined%20areas%2C%20questions%20were%20raised%20by%20health%20authorities%20and%20professional%20bodies%20about%20the%20possible%20risk%20of%20inducing%20rifampicin%20resistance%20among%20the%20M.%20tuberculosis%20strains%20circulating%20in%20these%20areas.%20This%20issue%20has%20not%20been%20addressed%20in%20scientific%20literature%20to%20date.%20To%20produce%20an%20authoritative%20consensus%20statement%20about%20the%20risk%20that%20SDR%20would%20induce%20rifampicin-resistant%20tuberculosis%2C%20a%20meeting%20was%20convened%20with%20tuberculosis%20%28TB%29%20and%20leprosy%20experts.%20The%20experts%20carefully%20reviewed%20and%20discussed%20the%20available%20evidence%20regarding%20the%20mechanisms%20and%20risk%20factors%20for%20the%20development%20of%20%28multi%29%20drug-resistance%20in%20M.%20tuberculosis%20with%20a%20view%20to%20the%20special%20situation%20of%20the%20use%20of%20SDR%20as%20PEP%20for%20leprosy.%20They%20concluded%20that%20SDR%20given%20to%20contacts%20of%20leprosy%20patients%2C%20in%20the%20absence%20of%20symptoms%20of%20active%20TB%2C%20poses%20a%20negligible%20risk%20of%20generating%20resistance%20in%20M.%20tuberculosis%20in%20individuals%20and%20at%20the%20population%20level.%20Thus%2C%20the%20benefits%20of%20SDR%20prophylaxis%20in%20reducing%20the%20risk%20of%20developing%20leprosy%20in%20contacts%20of%20new%20leprosy%20patients%20far%20outweigh%20the%20risks%20of%20generating%20drug%20resistance%20in%20M.%20tuberculosis.%22%2C%22date%22%3A%22June%208%2C%202016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40249-016-0140-y%22%2C%22ISSN%22%3A%222049-9957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40249-016-0140-y%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T16%3A18%3A45Z%22%7D%7D%2C%7B%22key%22%3A%2277H4JAIT%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mougari%20et%20al.%22%2C%22parsedDate%22%3A%222016-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMougari%2C%20F.%2C%20Amarsy%2C%20R.%2C%20Veziris%2C%20N.%2C%20Bastian%2C%20S.%2C%20Brossier%2C%20F.%2C%20Ber%26%23xE7%3Bot%2C%20B.%2C%20Raskine%2C%20L.%20and%20Cambau%2C%20E.%20%282016%29.%20%3Cb%3EStandardized%20interpretation%20of%20antibiotic%20susceptibility%20testing%20and%20resistance%20genotyping%20for%20Mycobacterium%20abscessus%20with%20regard%20to%20subspecies%20and%20erm41%20sequevar%3C%5C%2Fb%3E.%20J%20Antimicrob%20Chemother%20%3Ci%3E71%3C%5C%2Fi%3E%2C%202208%26%23x2013%3B2212%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw130%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw130%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Standardized%20interpretation%20of%20antibiotic%20susceptibility%20testing%20and%20resistance%20genotyping%20for%20Mycobacterium%20abscessus%20with%20regard%20to%20subspecies%20and%20erm41%20sequevar%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rishma%22%2C%22lastName%22%3A%22Amarsy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvaine%22%2C%22lastName%22%3A%22Bastian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9atrice%22%2C%22lastName%22%3A%22Ber%5Cu00e7ot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%20The%20objective%20of%20this%20study%20was%20to%20provide%20standardized%20antibiotic%20susceptibility%20testing%20%28AST%29%20for%20Mycobacterium%20abscessus%20with%20regard%20to%20subspecies.%5CnMethods%20One%20hundred%20and%20sixty-five%20clinical%20isolates%20were%20tested%20for%20susceptibility%20to%2015%20antibiotics%20using%20a%20commercial%20microdilution%20method%2C%20at%20two%20reading%20times%3A%20%28i%29%20early%20reading%20time%20%28ERT%29%2C%20when%20the%20growth%20control%20was%20first%20positive%3B%20and%20%28ii%29%20late%20reading%20time%20%28LRT%29%2C%20of%2014%20days%2C%20for%20detecting%20inducible%20resistance.%20In%20addition%2C%20genes%20or%20mutations%20involved%20in%20resistance%20were%20studied%20%5Berm%2841%29%2C%20rrl%20and%20rrs%5D.%5CnResults%20Three%20patterns%20were%20observed%20for%20clarithromycin%3A%20%28i%29%20MIC%20%3E16%20mg%5C%2FL%20at%20ERT%20%28median%205%20days%29%20for%2015%20isolates%20%5B10%20subsp.%20abscessus%20erm%2841%29%20sequevar%20T28%2C%203%20subsp.%20bolletii%20and%202%20subsp.%20massiliense%5D%20among%20which%209%20harboured%20an%20a2058g%5C%2Fc%20rrl%20mutation%3B%20%28ii%29%20MIC%20%5Cu226416%20mg%5C%2FL%20at%20ERT%2C%20but%20%3E16%20mg%5C%2FL%20at%20LRT%2C%20for%20106%20isolates%20%5B84%20abscessus%20erm%2841%29%20T28%20and%2022%20bolletii%5D%20showing%20intrinsic%20inducible%20resistance%3B%20and%20%28iii%29%20MIC%20%5Cu22644%20mg%5C%2FL%20at%20ERT%20and%20LRT%20for%2044%20isolates%20%5B18%20abscessus%20erm%2841%29%20C28%20and%2026%20massiliense%5D.%20Amikacin%20MIC%20was%20%3E64%20mg%5C%2FL%20for%20eight%20isolates%20%5Bfive%20abscessus%20erm%2841%29%20T28%2C%20two%20massiliense%20and%20one%20bolletii%5D%20among%20which%20seven%20harboured%20the%20a1408g%20rrs%20mutation%2C%20but%20%5Cu226464%20mg%5C%2FL%20for%20the%20remaining%20isolates%20without%20mutation.%20For%20the%20other%20antibiotics%2C%20only%20one%20WT%20pattern%20was%20observed%2C%20with%20cefoxitin%2C%20tigecycline%20and%20linezolid%20showing%20MIC%20values%20compatible%20with%20susceptibility.%5CnConclusions%20Standard%20AST%20can%20predict%20clarithromycin%20and%20amikacin%20resistance%20using%20interpretation%20rules%20with%20regard%20to%20subspecies.%20For%20other%20antibiotics%2C%20since%20only%20one%20pattern%20is%20observed%2C%20there%20is%20no%20need%20for%20systematic%20phenotypic%20or%20genotypic%20testing.%22%2C%22date%22%3A%2208%5C%2F01%5C%2F2016%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkw130%22%2C%22ISSN%22%3A%220305-7453%2C%201460-2091%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjac.oxfordjournals.org%5C%2Fcontent%5C%2F71%5C%2F8%5C%2F2208%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-09-18T14%3A30%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22RZ6CP2V6%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mougari%20et%20al.%22%2C%22parsedDate%22%3A%222016-12-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMougari%2C%20F.%2C%20Guglielmetti%2C%20L.%2C%20Raskine%2C%20L.%2C%20Sermet-Gaudelus%2C%20I.%2C%20Veziris%2C%20N.%20and%20Cambau%2C%20E.%20%282016%29.%20%3Cb%3EInfections%20caused%20by%20Mycobacterium%20abscessus%3A%20epidemiology%2C%20diagnostic%20tools%20and%20treatment%3C%5C%2Fb%3E.%20Expert%20Review%20of%20Anti-infective%20Therapy%20%3Ci%3E14%3C%5C%2Fi%3E%2C%201139%26%23x2013%3B1154%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F14787210.2016.1238304%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F14787210.2016.1238304%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Infections%20caused%20by%20Mycobacterium%20abscessus%3A%20epidemiology%2C%20diagnostic%20tools%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Sermet-Gaudelus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22Introduction%3A%20Mycobacterium%20abscessus%20is%20an%20emerging%20mycobacteria%20that%20is%20responsible%20for%20lung%20diseases%20and%20healthcare-associated%20extrapulmonary%20infections.%20Recent%20findings%20support%20its%20taxonomic%20status%20as%20a%20single%20species%20comprising%203%20subspecies%20designated%20abscessus%2C%20bolletii%20and%20massiliense.%20We%20performed%20a%20review%20of%20English-language%20publications%20investigating%20all%20three%20of%20these%20subspecies.Areas%20covered%3A%20Worldwide%2C%20human%20infections%20are%20often%20attributable%20to%20environmental%20contamination%2C%20although%20the%20isolation%20of%20M.%20abscessus%20in%20this%20reservoir%20is%20very%20rare.%20Basic%20research%20has%20demonstrated%20an%20association%20between%20virulence%20and%20cell%20wall%20components%20and%20cording%2C%20and%20genome%20analysis%20has%20identified%20gene%20transfer%20from%20other%20bacteria.%20The%20bacteriological%20diagnosis%20of%20M.%20abscessus%20is%20based%20on%20innovative%20tools%20combining%20molecular%20biology%20and%20mass%20spectrometry.%20Genotypic%20and%20phenotypic%20susceptibility%20testing%20are%20required%20to%20predict%20the%20success%20of%20macrolide%20%28clarithromycin%20or%20azithromycin%29-based%20therapeutic%20regimens.%20Genotyping%20methods%20are%20helpful%20to%20assess%20relapse%20and%20cross-transmission%20and%20to%20search%20for%20a%20common%20source.%20Treatment%20is%20not%20standardised%2C%20and%20outcomes%20are%20often%20unsatisfactory.Expert%20commentary%3A%20M.%20abscessus%20is%20still%20an%20open%20field%20in%20terms%20of%20clinical%20and%20bacteriological%20research.%20Further%20knowledge%20of%20its%20ecology%20and%20transmission%20routes%2C%20as%20well%20as%20host-pathogen%20interactions%2C%20is%20required.%20Because%20the%20number%20of%20human%20cases%20is%20increasing%2C%20it%20is%20also%20necessary%20to%20identify%20more%20active%20treatments%20and%20perform%20clinical%20trials%20to%20assess%20standard%20effective%20regimens.%22%2C%22date%22%3A%22December%201%2C%202016%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F14787210.2016.1238304%22%2C%22ISSN%22%3A%221478-7210%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fdx.doi.org%5C%2F10.1080%5C%2F14787210.2016.1238304%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222017-08-02T14%3A39%3A50Z%22%7D%7D%2C%7B%22key%22%3A%22NFC657MC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pantel%20et%20al.%22%2C%22parsedDate%22%3A%222016-09-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPantel%2C%20A.%2C%20Petrella%2C%20S.%2C%20Veziris%2C%20N.%2C%20Matrat%2C%20S.%2C%20Bouige%2C%20A.%2C%20Ferrand%2C%20H.%2C%20Sougakoff%2C%20W.%2C%20Mayer%2C%20C.%20and%20Aubry%2C%20A.%20%282016%29.%20%3Cb%3EDescription%20of%20compensatory%20gyrA%20mutations%20restoring%20fluoroquinolone%20susceptibility%20in%20Mycobacterium%20tuberculosis%3C%5C%2Fb%3E.%20J%20Antimicrob%20Chemother%20%3Ci%3E71%3C%5C%2Fi%3E%2C%202428%26%23x2013%3B2431%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw169%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fjac%5C%2Fdkw169%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Description%20of%20compensatory%20gyrA%20mutations%20restoring%20fluoroquinolone%20susceptibility%20in%20Mycobacterium%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alix%22%2C%22lastName%22%3A%22Pantel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Petrella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Matrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Bouige%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Ferrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudine%22%2C%22lastName%22%3A%22Mayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%20Resistance%20to%20fluoroquinolones%20%28FQs%29%20in%20Mycobacterium%20tuberculosis%20%28Mtb%29%20is%20mainly%20due%20to%20mutations%20in%20DNA%20gyrase%20%28GyrA2B2%29%2C%20with%20the%20most%20common%20substitutions%20located%20at%20positions%2090%20and%2094%20in%20GyrA.%20Two%20clinical%20MDR%20Mtb%20%28MDR-TB%29%20strains%20harbouring%20an%20A90E%20or%20D94N%20substitution%20in%20GyrA%20were%20found%20to%20be%20surprisingly%20susceptible%20to%20FQs%20%28ofloxacin%20MIC%20%5Cu22642%20mg%5C%2FL%29.%20We%20studied%20the%20impact%20of%20the%20additional%20GyrA%20substitutions%20found%20in%20these%20strains%20%28T80A%20and%20T80A%20%2B%20A90G%2C%20respectively%29%20on%20FQ%20susceptibility.%5CnMethods%20Mutants%20of%20interest%20were%20generated%20by%20site-specific%20mutagenesis%20of%20GyrA%20alleles.%20WT%20and%20mutant%20TB%20DNA%20gyrase%20subunits%20were%20overexpressed%20in%20Escherichia%20coli%20and%20purified%2C%20and%20the%20in%20vitro%20susceptibility%20to%20FQs%20of%20their%20DNA%20supercoiling%20reaction%20was%20studied.%5CnResults%20IC50s%20of%20mutant%20gyrase%20complexes%20bearing%20GyrA%20D94N%20and%20A90E%20were%203-%20to%2036-fold%20higher%20than%20WT%20IC50s%2C%20whereas%20IC50s%20of%20gyrase%20bearing%20T80A%20%2B%20A90G%20%2B%20D94N%20and%20T80A%20%2B%20A90E%20were%20close%20to%20the%20WT%20IC50s.%5CnConclusions%20We%20demonstrated%20that%20substitutions%20T80A%20and%20A90G%20restore%20FQ%20susceptibility%20when%20associated%20with%20a%20substitution%20implicated%20in%20high-level%20FQ%20resistance.%20Line%20probe%20assay%20misclassification%20of%20MDR-TB%20strains%20as%20pre-XDR%20or%20XDR%20can%20be%20corrected%20by%20sequence%20analysis%20of%20gyrA.%22%2C%22date%22%3A%2209%5C%2F01%5C%2F2016%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1093%5C%2Fjac%5C%2Fdkw169%22%2C%22ISSN%22%3A%220305-7453%2C%201460-2091%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fjac.oxfordjournals.org%5C%2Fcontent%5C%2F71%5C%2F9%5C%2F2428%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222016-09-18T14%3A30%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22A9ZUD9JN%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parize%20et%20al.%22%2C%22parsedDate%22%3A%222016%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EParize%2C%20P.%2C%20Hamelin%2C%20A.%2C%20Veziris%2C%20N.%2C%20Morand%2C%20P.%20C.%2C%20Guillemain%2C%20R.%2C%20Lortholary%2C%20O.%20and%20Dupin%2C%20N.%20%282016%29.%20%3Cb%3EInduction%20therapy%20with%20linezolid%5C%2Fclarithromycin%20combination%20for%20Mycobacterium%20chelonae%20skin%20infections%20in%20immunocompromised%20hosts%3C%5C%2Fb%3E.%20Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology%20%3Ci%3E30%3C%5C%2Fi%3E%2C%20101%26%23x2013%3B105%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjdv.12965%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjdv.12965%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Induction%20therapy%20with%20linezolid%5C%2Fclarithromycin%20combination%20for%20Mycobacterium%20chelonae%20skin%20infections%20in%20immunocompromised%20hosts%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Parize%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Hamelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.C.%22%2C%22lastName%22%3A%22Morand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Guillemain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Lortholary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Dupin%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2201%5C%2F2016%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fjdv.12965%22%2C%22ISSN%22%3A%2209269959%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fdoi.wiley.com%5C%2F10.1111%5C%2Fjdv.12965%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-12T09%3A23%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22JYLD7TLG%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Raharolahy%20et%20al.%22%2C%22parsedDate%22%3A%222016-08-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERaharolahy%2C%20O.%2C%20Ramarozatovo%2C%20L.%20S.%2C%20Ranaivo%2C%20I.%20M.%2C%20Sendrasoa%2C%20F.%20A.%2C%20Andrianarison%2C%20M.%2C%20Andrianarivelo%2C%20M.%20R.%2C%20Cambau%2C%20E.%20and%20Rabenja%2C%20F.%20R.%20%282016%29.%20%3Cb%3EA%20Case%20of%20Fluoroquinolone-Resistant%20Leprosy%20Discovered%20after%209%20Years%20of%20Misdiagnosis%3C%5C%2Fb%3E.%20Case%20Reports%20in%20Infectious%20Diseases%20%3Ci%3E2016%3C%5C%2Fi%3E%2C%204632369%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1155%5C%2F2016%5C%2F4632369%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1155%5C%2F2016%5C%2F4632369%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20Case%20of%20Fluoroquinolone-Resistant%20Leprosy%20Discovered%20after%209%20Years%20of%20Misdiagnosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Onivola%22%2C%22lastName%22%3A%22Raharolahy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lala%20S.%22%2C%22lastName%22%3A%22Ramarozatovo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Irina%20M.%22%2C%22lastName%22%3A%22Ranaivo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fandresena%20A.%22%2C%22lastName%22%3A%22Sendrasoa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malalaniaina%22%2C%22lastName%22%3A%22Andrianarison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mala%20Rakoto%22%2C%22lastName%22%3A%22Andrianarivelo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fahafahantsoa%20Rapelanoro%22%2C%22lastName%22%3A%22Rabenja%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20a%20case%20of%20misdiagnosed%20leprosy%20in%20a%2021-year-old%20Malagasy%20male%2C%20who%2C%20improperly%20treated%2C%20developed%20secondary%20mycobacterial%20resistance%20to%20fluoroquinolone.%20The%20patient%20contracted%20the%20infection%209%20years%20prior%20to%20the%20current%20consultation%2C%20displaying%20on%20the%20right%20thigh%20a%20single%20papulonodular%20lesion%2C%20which%20progressively%20spread%20to%20the%20lower%20leg%2C%20back%2C%20and%20face.%20Initial%20administration%20of%20ciprofloxacin%20and%20prednisolone%20led%20to%20temporary%20and%20fluctuating%20improvement.%20Subsequent%20long-term%20self-medication%20with%20ciprofloxacin%20and%20corticosteroid%20did%20not%20heal%20the%20foul%20and%20nonhealing%20ulcers%20on%20the%20legs%20and%20under%20the%20right%20sole.%20Histopathological%20findings%20were%20compatible%20with%20lepromatous%20leprosy.%20Skin%20biopsy%20was%20positive%20for%20acid-fast%20bacilli%20and%20PCR%20assay%20confirmed%20the%20presence%20of%20a%20fluoroquinolone-resistant%20strain%20of%20Mycobacterium%20leprae%20%28gyrA%20A91V%29.%20After%206%20months%20of%20standard%20regimen%20with%20rifampicin%2C%20clofazimine%2C%20and%20dapsone%2C%20clinical%20outcome%20significantly%20improved.%20Clinical%20characteristics%20and%20possible%20epidemiological%20implications%20are%20discussed.%22%2C%22date%22%3A%222016-08-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1155%5C%2F2016%5C%2F4632369%22%2C%22ISSN%22%3A%222090-6625%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.hindawi.com%5C%2Fjournals%5C%2Fcriid%5C%2F2016%5C%2F4632369%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-11T23%3A32%3A17Z%22%7D%7D%5D%7D
Bernard, J., Armand-Lefèvre, L., Luce, E., Mniai, A. E., Chau, F., Casalino, E., Andremont, A. and Ruppé, E. (2016). Impact of a short exposure to levofloxacin on faecal densities and relative abundance of total and quinolone-resistant Enterobacteriaceae. Clinical Microbiology and Infection 22, 646.e1-646.e4, http://doi.org/10.1016/j.cmi.2016.04.015.
Bernard, C., Aubry, A., Chauffour, A., Brossier, F., Robert, J. and Veziris, N. (2016). In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. J Antimicrob Chemother, http://doi.org/10.1093/jac/dkw344.
Brossier, F. and Aubry, A. (2016). Résistance de Mycobacterium tuberculosis aux antituberculeux. Feuillets Bio 328, 17–25, http://doi.org/10.1684/abc.2016.1132.
Brossier, F., Guindo, D., Pham, A., Reibel, F., Sougakoff, W., Veziris, N. and Aubry, A. (2016). Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains. J Clin Microbiol 54, 1573–1580, http://doi.org/10.1128/JCM.00051-16.
Brossier, F., Cambau, E., Tessier, E., Jarlier, V. and Sougakoff, W. (2016). The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis. Tuberculosis 101, 144–145, http://doi.org/10.1016/j.tube.2016.09.028.
Brossier, F., Boudinet, M., Jarlier, V., Petrella, S. and Sougakoff, W. (2016). Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Tuberculosis 100, 15–24, http://doi.org/10.1016/j.tube.2016.06.002.
Chauffour, A., Robert, J., Veziris, N., Aubry, A. and Jarlier, V. (2016). Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium ulcerans Infection in Mice. PLOS Neglected Tropical Diseases 10, e0005066, http://doi.org/10.1371/journal.pntd.0005066.
Chazel, M., Marchandin, H., Keck, N., Terru, D., Carrière, C., Ponsoda, M., Jacomo, V., Panteix, G., Bouzinbi, N., Bañuls, A.-L., Choisy, M., Solassol, J., Aubry, A. and Godreuil, S. (2016). Evaluation of the SLOMYCO Sensititre® panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates. Annals of Clinical Microbiology and Antimicrobials 15, 30, http://doi.org/10.1186/s12941-016-0145-1.
Crabol, Y., Catherinot, E., Veziris, N., Jullien, V. and Lortholary, O. (2016). Rifabutin: where do we stand in 2016? J Antimicrob Chemother dkw024, http://doi.org/10.1093/jac/dkw024.
Fox, G. J., Benedetti, A., Mitnick, C. D., Pai, M., Menzies, D. and Mdr-Tb, T. C. G. for M.-A. of I. P. D. in (2016). Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis: Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLOS ONE 11, e0151724, http://doi.org/10.1371/journal.pone.0151724.
Fox, G. J., Mitnick, C. D., Benedetti, A., Chan, E. D., Becerra, M., Chiang, C.-Y., Keshavjee, S., Koh, W.-J., Shiraishi, Y., Viiklepp, P., Yim, J.-J., Pasvol, G., Robert, J., Shim, T. S., Shin, S. S., Menzies, Dick, Mdr-Tb, for the C. G. for M.-A. of I. P. D. in, Ahuja, S., Ashkin, D., Avendaño, M., Banerjee, R., Bauer, M., Burgos, M., Centis, R., Cobelens, F., Cox, H., D’Ambrosio, L., Lange, W. C. M. de, DeRiemer, K., Enarson, D., Falzon, D., Flanagan, K., Flood, J., Gandhi, N., Garcia-Garcia, L., Granich, R. M., Hollm-Delgado, M. G., Holtz, T. H., Hopewell, P., Iseman, M., Jarlsberg, L. G., Kim, H. R., Lancaster, J., Lange, C., Leimane, V., Leung, C. C., Li, J., Menzies, D., Migliori, G. B., Narita, M., Nathanson, E., Odendaal, R., O’Riordan, P., Pai, M., Palmero, D., Park, S. K., Pena, J., Pérez-Guzmán, C., Ponce-de-Leon, A., Quelapio, M. I. D., Quy, H. T., Riekstina, V., Royce, S., Salim, M., Schaaf, H. S., Seung, K. J., Shah, L., Shean, K., Sifuentes-Osornio, J., Sotgiu, G., Strand, M. J., Sung, S. W., Tabarsi, P., Tupasi, T. E., Vargas, M. H., Altena, R. van, Walt, M. van der, Werf, T. S. van der, Westenhouse, J. and Yew, W. W. (2016). Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis 62, 887–895, http://doi.org/10.1093/cid/ciw002.
Guglielmetti, L., Dû, D. L., Veziris, N., Caumes, E., Marigot-Outtandy, D., Yazdanpanah, Y., Robert, J. and Fréchet-Jachym, M. (2016). Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? European Respiratory Journal 48, 582–585, http://doi.org/10.1183/13993003.00411-2016.
Henry, B., Revest, M., Dournon, N., Epelboin, L., Mellon, G., Bellaud, G., Mordant, P., Le Dû, D., Véziris, N., Bernard, C., Morel, S., Jauréguiberry, S., Michelet, C., Bricaire, F., Tattevin, P. and Caumes, É. (2016). Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009–2014. Emerging Infectious Diseases 22, 518–521, http://doi.org/10.3201/eid2203.151130.
Lachâtre, M., Rioux, C., Dû, D. L., Fréchet-Jachym, M., Veziris, N., Bouvet, E. and Yazdanpanah, Y. (2016). Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis 16, 294, http://doi.org/10.1016/S1473-3099(16)00047-5.
Lafeuille, E., Veziris, N., Sougakoff, W., Roure, F., Le Dû, D., Dournon, N., Caumes, E., Jarlier, V., Aubry, A., Robert, J. and Bernard, C. (2016). XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions. Médecine et Maladies Infectieuses 46, 52–55, http://doi.org/10.1016/j.medmal.2015.12.008.
Lange, C., Duarte, R., Fréchet-Jachym, M., Guenther, G., Guglielmetti, L., Olaru, I. D., Oliveira, O., Rumetshofer, R., Veziris, N. and van Leth, F. (2016). Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. Am J Respir Crit Care Med 194, 1029–1031, http://doi.org/10.1164/rccm.201606-1097LE.
Lortholary, O., Roussillon, C., Boucherie, C., Padoin, C., Chaix, M.-L., Breton, G., Rami, A., Veziris, N., Patey, O., Caumes, E., May, T., Molina, J.-M., Robert, J., Tod, M., Fagard, C. and Chêne, G. (2016). Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial. Journal of Antimicrobial Chemotherapy 71, 783–793, http://doi.org/10.1093/jac/dkv384.
Mieras, L., Anthony, R., van Brakel, W., Bratschi, M. W., van den Broek, J., Cambau, E., Cavaliero, A., Kasang, C., Perera, G., Reichman, L., Richardus, J. H., Saunderson, P., Steinmann, P. and Yew, W. W. (2016). Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infectious Diseases of Poverty 5, 46, http://doi.org/10.1186/s40249-016-0140-y.
Mougari, F., Amarsy, R., Veziris, N., Bastian, S., Brossier, F., Berçot, B., Raskine, L. and Cambau, E. (2016). Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother 71, 2208–2212, http://doi.org/10.1093/jac/dkw130.
Mougari, F., Guglielmetti, L., Raskine, L., Sermet-Gaudelus, I., Veziris, N. and Cambau, E. (2016). Infections caused by Mycobacterium abscessus: epidemiology, diagnostic tools and treatment. Expert Review of Anti-infective Therapy 14, 1139–1154, http://doi.org/10.1080/14787210.2016.1238304.
Pantel, A., Petrella, S., Veziris, N., Matrat, S., Bouige, A., Ferrand, H., Sougakoff, W., Mayer, C. and Aubry, A. (2016). Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis. J Antimicrob Chemother 71, 2428–2431, http://doi.org/10.1093/jac/dkw169.
Parize, P., Hamelin, A., Veziris, N., Morand, P. C., Guillemain, R., Lortholary, O. and Dupin, N. (2016). Induction therapy with linezolid/clarithromycin combination for Mycobacterium chelonae skin infections in immunocompromised hosts. Journal of the European Academy of Dermatology and Venereology 30, 101–105, http://doi.org/10.1111/jdv.12965.
Raharolahy, O., Ramarozatovo, L. S., Ranaivo, I. M., Sendrasoa, F. A., Andrianarison, M., Andrianarivelo, M. R., Cambau, E. and Rabenja, F. R. (2016). A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis. Case Reports in Infectious Diseases 2016, 4632369, http://doi.org/10.1155/2016/4632369.